Methods and compositions for immune protection against extra-intestinal pathogenic E. coli
Jan Theunis Poolman, Haalem (NL); Bert Jacquemyn, Mechelen (BE); Darren Robert Abbanat, Cornwall, NY (US); Patricia Ibarra Yon, Solothurn (CH); Peter Wilhelmus Maria Hermans, Huissen (NL); Michael Thomas Kowarik, Zurich (CH); Michael Lukas Wetter, Zurich (CH); Stefan Jochen Kemmler, Zurich (CH); Micha Andres Häuptle, Zurich (CH); Veronica Gambillara Fonck, Meilen (CH); and Manuela Mally, Watt (CH)
Assigned to Janssen Pharmaceuticals, Inc., Titusville, NJ (US); and GlaxosSmithKline Biologicals S.A., (BE)
Filed by Glaxosmithkline Biologicals S.A., Rixensart (BE); and Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed on Sep. 23, 2022, as Appl. No. 17/934,781.
Application 17/934,781 is a continuation of application No. 16/781,526, filed on Feb. 4, 2020, granted, now 11,484,582.
Application 16/781,526 is a continuation of application No. 15/754,867, granted, now 10,583,185, previously published as PCT/US2016/048278, filed on Aug. 24, 2016.
Claims priority of provisional application 62/210,655, filed on Aug. 27, 2015.
Claims priority of provisional application 62/209,091, filed on Aug. 24, 2015.
Prior Publication US 2023/0062987 A1, Mar. 2, 2023
1. A composition comprising an E. coli O25B antigen polysaccharide at a first concentration, and E. coli O1A, O2 and O6A antigen polysaccharides each at a concentration that is independently 40% or 50% of the first concentration, each of the E. coli O25B, O1A, O2 and O6A antigen polysaccharides are independently covalently bound to a carrier protein, and the first concentration is 8 to 48 μg/ml.